SAN FRANCISCO - A restructured global immuno-oncology deal between Regeneron Pharmaceuticals Inc. and Sanofi SA means "we're now pretty much in control of our entire pipeline of oncology agents," Regeneron's founder and CEO, Len Schleifer, told attendees at the J.P. Morgan Healthcare Conference on Monday. (See BioWorld, Oct. 2, 2018.)